This groundbreaking achievement marks a significant step forward for Morocco’s pharmaceutical sector and its commitment to leveraging the potential of cannabis for medical purposes.
The new drug, Cannabidiol Pharma 5, is designed to treat refractory epilepsy, a condition affecting thousands of Moroccans, particularly children.
The drug is produced using a fully integrated process, from cultivation to final product. It is formulated to be THC-free, ensuring safety and efficacy. The launch of this medication is expected to provide a much-needed treatment option for patients suffering from this debilitating condition.
Morocco’s investment in medical cannabis research and development demonstrates the country’s potential to become a global leader in the pharmaceutical industry. As the regulatory landscape for medical cannabis continues to evolve, Morocco is well-positioned to capitalize on this emerging market.
WN/as/APA